Why the study?
Does ticagrelor improve outcomes compared to other P2Y12 antagonists in patients with acute coronary syndromes?
Does ticagrelor improve outcomes compared to other P2Y12 antagonists in patients with acute coronary syndromes?
Ticagrelor is a novel P2Y12 antagonist that offers potential advantages over clopidogrel for the treatment of acute coronary syndromes.
May support ticagrelor over clopidogrel in ACS; leaves open direct outcome comparisons with other P2Y12 inhibitors.
Agents that inhibit platelet function are used routinely in the treatment and prevention of acute coronary syndromes. The main antiplatelet treatments used combine aspirin with one of the thienopyridine P2Y(12) antagonists, either clopidogrel or prasugrel. By blocking the synthesis of thromboxane A(2) in platelets and by blocking the effects of ADP, respectively, these agents reduce platelet activity, platelet aggregation and thrombus formation. Ticagrelor (marketed by AstraZeneca as Brilinta™ in the USA, and as Brilique(®) or Possia(®) in Europe) is a cyclopentyl-triazolo-pyrimidine, a new chemical class of P2Y(12) antagonist that is now approved for use in the wide spectrum of acute coronary syndromes. In this article we provide an overview of ticagrelor. We discuss the differences in mode of action compared with other P2Y(12) antagonists, examine its pharmacodynamic, pharmacokinetic and safety profile, and summarize the various clinical trials that have provided information on its efficacy in combination with aspirin. Ticagrelor appears to overcome some of the difficulties that have been encountered with other antiplatelet treatments, clopidogrel in particular.
No takes yet. Share an insight, caveat, or question.
Wijeyeratne et al. (2012) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: